TABLE 1.
EC50s of compounds and replication levelsa for wild-type and lamivudine-resistant HBV mutants following a 10 μM treatment
| Compound | Wild type
|
M552I
|
M552V
|
L528M/M552V
|
||||
|---|---|---|---|---|---|---|---|---|
| EC50 | Replication level | EC50 | Replication level | EC50 | Replication level | EC50 | Replication level | |
| Lamivudine | 0.56b | 1.3 ± 0.2b | >80c | 176.8 ± 17.9b | 33c | 76.9 ± 15.8b | >80c | 126.7 ± 9.6b |
| Adefovir | 0.58b | 10.5 ± 6.1b | 4.5c | 30.8 ± 20.0b | 4.9c | 32.5 ± 2.9b | 2.2c | 23.8 ± 13.3b |
| MCC-478 | 0.027 | 9.0 ± 14.4 | 2.6 | 13.1 ± 9.5 | 3.3 | 32.1 ± 10.4 | 2.0 | 9.1 ± 6.9 |
a
Numbers indicate the mean ± standard deviation from two to four experiments in replication percent for wild-type and mutant HBV transfected into HuH-7 cells and treated with 10 μM concentrations of the indicated compounds. Single-stranded bands were quantified using a LAS1000 image analyzer (Fuji Photo Film) and normalized for transfection efficiency based on β-galactosidase activity. Single-stranded control bands (without treatment) were set as 100%.
b
See reference 21.
c
See reference 23.